Skip to search formSkip to main contentSkip to account menu

onabotulinumtoxinA 200 UNT Injection [Botox]

Known as: Botox 200 UNT Injection, botulinum toxin type A 200 [USP'U] INTRADERMAL INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION [BOTOX], Botox 200 UNT/ML Injectable Solution 
National Institutes of Health

Related topics

Related topics

7 relations
Albumin Human, USPBotoxBotulinum Toxin Type AInjection

Broader (1)

onabotulinumtoxinA 200 UNT Injection

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2017
Review
2017
Sphincter of Oddi Function and Risk Factors for Dysfunction
The sphincter of Oddi (SO) is a smooth muscle valve regulating the flow of biliary and pancreatic secretions into the duodenum… 
Highly Cited
2016
Highly Cited
2016
A two years open-label prospective study of OnabotulinumtoxinA 195 U in medication overuse headache: a real-world experience
BackgroundThe efficacy and safety of OnabotulinumtoxinA (BOTOX®) in adults with chronic migraine (CM) were demonstrated in the… 
Review
2016
Review
2016
Conversion Ratio between Botox®, Dysport®, and Xeomin® in Clinical Practice
Botulinum neurotoxin has revolutionized the treatment of spasticity and is now administered worldwide. There are currently three… 
Review
2014
Review
2014
Outcome After Anal Intrasphincteric Botox Injection in Children With Surgically Treated Hirschsprung Disease
Objectives: A nonrelaxing internal anal sphincter is present in a relatively large proportion of children with surgically treated… 
Highly Cited
2010
Highly Cited
2010
Efficacy and safety of onabotulinumtoxinA for idiopathic overactive bladder: a double-blind, placebo controlled, randomized, dose ranging trial.
Highly Cited
2010
Highly Cited
2010
Content of Botulinum Neurotoxin in Botox®/Vistabel®, Dysport®/Azzalure®, and Xeomin®/Bocouture®
AbstractBackground: Botulinum neurotoxin type A (BoNT/A) is the active substance in preparations used for the highly effective… 
Highly Cited
2009
Highly Cited
2009
Comparative study of Botox® injection treatment for upper eyelid retraction with 6-month follow-up in patients with thyroid eye disease in the congestive or fibrotic stage
AimTo compare morphometric data of the eyelid fissure and the levator muscle function (LF) before and up to 6 months after… 
Review
2008
Review
2008
Evidence-based systematic review on the efficacy and safety of botulinum toxin-A therapy in post-stroke spasticity
SummaryBackground. Botulinum toxin type A (BoNTA) has been suggested as an effective anti-spastic drug. In this article, we… 
Highly Cited
2006
Highly Cited
2006
Efficacy and safety of a new Botulinum Toxin Type A free of complexing proteins in the treatment of blepharospasm
Summary.NT 201 is a new development of Botulinum Toxin Type A free of complexing proteins. In this double-blind Phase III trial… 
Highly Cited
1999
Highly Cited
1999
Medium‐term response characterisation and risk factor analysis of botulinum toxin type A in the management of spasticity in children with cerebral palsy
We prospectively studied the medium‐term effects of botulinum toxin type A (BTX‐A) treatment in 197 children with cerebral palsy… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)